Invivyd, Inc. (IVVD)
NASDAQ: IVVD · IEX Real-Time Price · USD
-0.105 (-3.44%)
At close: Apr 12, 2024, 4:00 PM
+0.060 (2.03%)
After-hours: Apr 12, 2024, 4:16 PM EDT

Company Description

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.

The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2.

It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses.

The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022.

Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Invivyd, Inc.
Invivyd logo
Country United States
Founded 2020
IPO Date Aug 6, 2021
Industry Biotechnology
Sector Healthcare
Employees 94
CEO David Hering M.B.A.

Contact Details

1601 Trapelo Road, Suite 178
Waltham, Massachusetts 02451
United States
Phone (781) 819-0080

Stock Details

Ticker Symbol IVVD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001832038
CUSIP Number 00534A102
ISIN Number US00534A1025
Employer ID 85-1403134
SIC Code 2836

Key Executives

Name Position
David Hering M.B.A. Chief Executive Officer and Director
Jill Andersen J.D. Chief Legal Officer and Corporate Secretary
William E. Duke Jr., M.B.A. Chief Financial Officer
Jeremy Gowler Chief Operating Officer and Chief Commercial Officer
Stacy Price M.S. Chief Technology and Manufacturing Officer
Dr. Robert D. Allen Ph.D. Chief Scientific Officer
Scott Young Senior Vice President of Investor Relations and Corporate Communications
Julie Green M.B.A. Chief Human Resources Officer
Heidi Spurling M.S. Vice President of Strategy and Operations and Chief of Staff to the Chief Executive Officer

Latest SEC Filings

Date Type Title
Apr 12, 2024 8-K Current Report
Apr 4, 2024 8-K Current Report
Mar 28, 2024 10-K Annual Report
Mar 28, 2024 8-K Current Report
Mar 25, 2024 8-K Current Report
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 S-3 Registration statement under Securities Act of 1933
Feb 9, 2024 8-K Current Report
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals